Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


ViewPoint Therapeutics
953 Indiana St.
San Francisco, CA 94107
Phone: 734-205-8246
http://www.viewpointtherapeutics.com/

ViewPoint is a preclinical-stage biotechnology company passionately committed to the discovery, development, and commercialization of treatments for diseases of protein misfolding, which is implicated in numerous common disorders of aging including cataracts and presbyopia. The Company was founded in 2014 based on technology developed in the lab of ViewPoint co-founder, Dr. Jason Gestwicki, at the University of Michigan in collaboration with the lab of Dr. Usha Andley at Washington University in St. Louis. ViewPoint has a world-class Scientific Advisory Board with decades of experience in the fields of protein misfolding, crystallin biology, cataract etiology and medicinal chemistry. Targeting α-crystallin, a genetically validated target that drives cataract pathology and presbyopia, ViewPoint is developing VP1-001, a small molecule that is active in preclinical models of age-related cataracts. VP1-001 is the first preclinical candidate from ViewPoint's discovery engine.

Key Contact
NameTitleE-Mail
Leah MakleyCEOleah@viewpointtherapeutics.com


Funding Events
DateAmountTypeInvestors
03/12/18$35,000,000Series B Biotechnology Value Fund
Lagunita
Mission Bay Capital
Novo Holdings
The Rise Fund  
University of Michigan
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.